Fabian Acker

First-line #EGFR+ #NSCLC is rapidly evolving with more effective systemic strategies. But is there a “third way” of intensification? In our meta-analysis just published in @JTOonline, integrating LAT with EGFR TKIs significantly improved PFS and OS with acceptable safety. ➡️ Upfront integration in 1L may be where LAT expresses its full potential. Grateful to all co-authors and especially @Brunet3Leon for leading this effort. @dplanchard @BRicciutiMD @JuliaRotow @APassaroMD @thenasheffect @AminNassarMD @adib_elio @GiuliaLaCavaMD @valentsant @RobertoFerrara_ @HendriksLizza @finn_corinne @FabianAckerMD @derosa__lisa @IASLC @PoliclinCampus @CampusBioMedico @ImperialSandC 🔗 jto.org/article/S1556-…

🚀 Immunotherapies are safe and effective in patients with lung cancer and a history of allogeneic hematopoietic cell transplantation. Happy that our work was valued with a best poster award at #ELCC2026.

Reconstructing individual patient survival data (IPD) for scientific re-use has never been as easy as it is with V-Exploder (v-exploder.com). Happy to announce that the video tutorial is out: youtu.be/X1PSf62ew1U?si… 🚀

Out now in @Annals_Oncology👇 When the control arm is already a great option, detecting progress requires more than a HR, and this is particularly true for 1st line combos in #EGFRve #NSCLC Our RMST reanalysis led by @FabianAckerMD of FLAURA2 & MARIPOSA highlights delayed but real survival gains, helping define when benefit begins, and how much it truly matters! @myESMO @IASLC annalsofoncology.org/article/S0923-…